Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Research & Development: 2017-2024

Historic Research & Development for DiaMedica Therapeutics (DMAC) over the last 8 years, with Dec 2024 value amounting to $19.1 million.

  • DiaMedica Therapeutics' Research & Development rose 24.19% to $1.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was $7.9 million, marking a year-over-year increase of 74.70%. This contributed to the annual value of $19.1 million for FY2024, which is 45.36% up from last year.
  • Latest data reveals that DiaMedica Therapeutics reported Research & Development of $19.1 million as of FY2024, which was up 45.36% from $13.1 million recorded in FY2023.
  • In the past 5 years, DiaMedica Therapeutics' Research & Development ranged from a high of $19.1 million in FY2024 and a low of $7.8 million during FY2022.
  • Moreover, its 3-year median value for Research & Development was $13.1 million (2023), whereas its average is $13.3 million.
  • Its Research & Development has fluctuated over the past 5 years, first dropped by 10.56% in 2022, then surged by 67.24% in 2023.
  • Yearly analysis of 5 years shows DiaMedica Therapeutics' Research & Development stood at $8.2 million in 2020, then rose by 6.83% to $8.8 million in 2021, then declined by 10.56% to $7.8 million in 2022, then spiked by 67.24% to $13.1 million in 2023, then skyrocketed by 45.36% to $19.1 million in 2024.